350
Participants
Start Date
September 30, 2025
Primary Completion Date
June 30, 2027
Study Completion Date
December 31, 2028
MyRisk Hereditary Cancer Test
Subjects that are planning to proceed with OCS and enrolled in the trial will be contacted by the genetics clinician (by telephone or in person, based on subject preference) to review the option for HCS in addition to OCS. The WCM genetics clinician will review the potential risks and benefits, possible findings, and implications of findings for HCS. The genetics clinician will follow WCM standards (outlined by the WCM Genetics and Personalized Cancer Prevention Program https://wcinyp.org/GPCP) for informed consent counseling on the potential risks/benefits of HCS. The counseling regarding OCS will have already been performed by the obstetrical team as part of the standard of care. The genetics clinician will review that OCS is being performed as part of the patient's standard of care prenatal visit and HCS is an additional component that is being performed as part of participation in this clinical trial.
Weill Cornell Medicine, New York
NewYork-Presbyterian Weill Cornell Medicine, Brooklyn
NewYork-Presbyterian Weill Cornell Medicine Queens, Queens
Weill Medical College of Cornell University
OTHER